Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group

Annals of Surgical Oncology

Volumn 22, Issue 8, 2015, Pages 2685-2699

  Singh, Simron ^a   Dey, Chris ^b   Kennecke, Hagen ^c   Kocha, Walter ^d   Maroun, Jean ^e   Metrakos, Peter ^f   Mukhtar, Tariq ^g   Pasieka, Janice ^h   Rayson, Daniel ⁱ   Rowsell, Corwyn ^b   Sideris, Lucas ^j   Wong, Ralph ^k   Law, Calvin ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d LONDON REGIONAL CANCER PROGRAM   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f ROYAL VICTORIA HOSPITAL   (Canada)

^g Havas Life Toronto   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^j MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^k ST BONIFACE GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; PANCREAS POLYPEPTIDE; PANCREASTATIN; SOMATOSTATIN DERIVATIVE;

ALGORITHM; ARTICLE; CANADIAN; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CLINICAL FEATURE; CONSENSUS; EPIDEMIC; HEALTH PRACTITIONER; HISTOPATHOLOGY; HORMONE RELEASE; HUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TREATMENT INDICATION; CANADA; CLASSIFICATION; CONSENSUS DEVELOPMENT; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

CANADA; CONSENSUS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84938288360     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4145-0     Document Type: Article

References (110)

1. Kocha W, Maroun J, Kennecke H, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17:49–64.
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469–92. doi:10.1053/j.gastro.2008.05.047.
3. Ellison TA, Edil BH. The current management of pancreatic neuroendocrine tumors. Adv Surg 2012;46:283–96.
4. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044–9. doi:10.1200/JCO.2011.35.1817
5. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14:5377–84.
6. Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98–119. doi:10.1159/000335591.
7. Kulke MH, Benson AB III, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10:724–64.
8. O’Toole D, Salazar R, Falconi M, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology. 2006;84:189–95. doi:10.1159/000098011.
9. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211. doi:10.1159/000098012.
10. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. doi:10.1200/JCO.2007.15.4377.
11. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis, and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33. doi:10.1093/annonc/mdn351.
12. Cukier M, Law C, Liu N, et al. Epidemiology and survival of neuroendocrine tumors in Ontario: a 15-year population-based study [abstract]. J Clin Oncol. 2012;30.
13. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12. doi:10.1097/MPA.0b013e3181ec124e.
14. Bosman T, Carneiro F, Hruban R, Theise N. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010. pp. 13–14.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
16. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401. doi:10.1007/s00428-006-0250-1.
17. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–62. doi:10.1007/s00428-007-0452-1.
18. Tang L, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with carcinoma of the endocrine pancreas. College of American Pathologists (CAP); 2013. Pancreas Endocrine 3.2.0.1.
19. Chejfec G, Falkmer S, Grimelius L, et al. Synaptophysin: a new marker for pancreatic neuroendocrine tumors. Am J Surg Pathol. 1987;11:241–7.
20. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A: biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427–43. doi:10.1245/s10434-010-1006-3.
21. Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–49. doi:10.1056/NEJMra021405.
22. Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A. 1986;83:3500–4.
23. Bridger JM, Kill IR, Lichter P. Association of pKi-67 with satellite DNA of the human genome in early G1 cells. Chromosome Res. 1998;6:13–24.
24. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 1992;25:31–40.
25. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257:231–7. doi:10.1006/excr.2000.4888.
26. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22. doi:10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.
27. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300–13. doi:10.1097/PAS.0b013e3181ce1447.
28. Craig J, Cheung M, Law C, Singh S. Ki-67 index variability in neuroendocrine tumors [abstract]. EMSO. 2012; abstract 1158P 2012.
29. Zerbi A, Falconi M, Rindi G, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010;105:1421–9. doi:10.1038/ajg.2009.747.
30. Cheslyn-Curtis S, Sitaram V, Williamson RC. Management of nonfunctioning neuroendocrine tumours of the pancreas. Br J Surg. 1993;80:625–7.
31. Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic nonfunctioning tumors. Neuroendocrinology. 2012;95:120–34. doi:10.1159/000335587.
32. White TJ, Edney JA, Thompson JS, Karrer FW, Moor BJ. Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg. 1994;168:627–9.
33. Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011;150:75–82. doi:10.1016/j.surg.2011.02.022.
34. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–803. doi:10.1158/1078-0432.CCR-08-0734.
35. Han JH, Kim MH, Moon SH, et al. Clinical characteristics and malignant predictive factors of pancreatic neuroendocrine tumors. Korean J Gastroenterol. 2009;53:98–105.
36. La RS, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323–33.
37. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–92. doi:10.1677/erc.1.01017.
38. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7. doi:10.1200/JCO.2010.33.0688.
39. Singh S, et al. [Abstract] The role of Ki-67 in the prognosis and management of neuroendocrine (NET) patients in a multidisciplinary cancer center. Gastrointestinal Cancers Symposium, 2012; (suppl 4; abstr 184).
40. Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19:195–211. doi:10.1016/j.beem.2004.11.013.
41. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab. 2007;21:43–68. doi:10.1016/j.beem.2007.01.003.
42. Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology. 2009;90:167–83. doi:10.1159/000184855.
43. Figueiredo FA, Giovannini M, Monges G, et al. Pancreatic endocrine tumors: a large single-center experience. Pancreas. 2009;38:936–40. doi:10.1097/MPA.0b013e3181b365db.
44. Jhala NC, Jhala DN, Chhieng DC, Eloubeidi MA, Eltoum IA. Endoscopic ultrasound-guided fine-needle aspiration: a cytopathologist’s perspective. Am J Clin Pathol. 2003;120:351–67. doi:10.1309/MFRF-J0XY-JLN8-NVDP.
45. Kocjan G. Fine-needle aspiration cytology of the pancreas: a guide to the diagnostic approach. Coll Antropol. 2010;34:749–56.
46. Pais SA, Al-Haddad M, Mohamadnejad M, et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc. 2010;71:1185–93. doi:10.1016/j.gie.2009.12.006.
47. Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18(Suppl 1):S27–S51. doi:10.1530/ERC-10-0282.
48. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85. doi:10.1158/1078-0432.CCR-09-1759.
49. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713–34. doi:10.1097/MPA.0b013e3181ebaffd.
50. Krausz Y, Freedman N, Rubinstein R, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (1)(1)(1)In-DTPA-octreotide (OctreoScan(R)). Mol Imaging Biol. 2011;13:583–93. doi:10.1007/s11307-010-0374-1.
51. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–47. doi:10.1053/j.semnuclmed.2006.03.007.
52. Singh S, Law C. Chromogranin A: A sensitive biomarker for the detection and posttreatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2012;6:313–34. doi:10.1586/egh.12.15.
53. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96:3741–9. doi:10.1210/jc.2011-0666.
54. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18(Suppl 1):S17–S25. doi:10.1530/ERC-10-0280.
55. 55.Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest. 2004;27:6–11.
56. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41:508–11. doi:10.1097/MPA.0b013e318243a0b6.
57. Rustagi S, Warner RR, Divino CM. Serum pancreastatin: the next predictive neuroendocrine tumor marker. J Surg Oncol. 2013;108:126–8. doi:10.1002/jso.23359.
58. Kvols LK, Brendtro KL. The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. Pancreas. 2010;39:705–6. doi:10.1097/MPA.0b013e3181eb7451.
59. Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152:965–74. doi:10.1016/j.surg.2012.08.038.
60. Libutti SK, Inabnet WB III. Force or stratagem? Surgery. 2012;152:975–6. doi:10.1016/j.surg.2012.08.061.
61. Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P. Enucleation of pancreatic neoplasms. Br J Surg. 2007;94:1254–9. doi:10.1002/bjs.5833.
62. Hellman P, Goretzki P, Simon D, Dotzenrath C, Roher HD. Therapeutic experience of 65 cases with organic hyperinsulinism. Langenbecks Arch Surg. 2000;385:329–36.
63. 63.Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet cell tumors arising in the head of the pancreas. Surgery. 1998;124:1056–61.
64. Rothmund M, Angelini L, Brunt LM, et al. Surgery for benign insulinoma: an international review. World J Surg. 1990;14:393–8.
65. Muller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg. 2007;246:966–74. doi:10.1097/SLA.0b013e31815c2ca3.
66. Smith JK, Ng SC, Hill JS, et al. Complications after pancreatectomy for neuroendocrine tumors: a national study. J Surg Res. 2010;163:63–8. doi:10.1016/j.jss.2010.04.017.
67. Abu HM, McPhail MJ, Zeidan BA, Jones CE, Johnson CD, Pearce NW. Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. is it worth it? JOP. 2009;10:276–9.
68. Bonney GK, Gomez D, Rahman SH, et al. Results following surgical resection for malignant pancreatic neuroendocrine tumours: a single institutional experience. JOP. 2008;9:19–25.
69. 69.Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88–92.
70. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg. 1996;20:908–14.
71. Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845–51. doi:10.1097/01.sla.0000246951.21252.60.
72. Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control. 2008;15:314–21.
73. Kleine M, Schrem H, Vondran FW, Krech T, Klempnauer J, Bektas H. Extended surgery for advanced pancreatic endocrine tumours. Br J Surg. 2012;99:88–94. doi:10.1002/bjs.7681.
74. Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138:859–66. doi:10.1001/archsurg.138.8.859.
75. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery. 2002;132:976–82. doi:10.1067/msy.2002.128615.
76. Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg. 2002;6:147–57.
77. Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg. 1999;3:233–43.
78. Kouvaraki MA, Solorzano CC, Shapiro SE, et al. Surgical treatment of nonfunctioning pancreatic islet cell tumors. J Surg Oncol. 2005;89:170–85. doi:10.1002/jso.20178.
79. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935–49. doi:10.1016/j.gassur.2004.09.046.
80. Cusati D, Zhang L, Harmsen WS, et al. Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J Am Coll Surg. 2012;215:117–24. doi:10.1016/j.jamcollsurg.2012.05.002.
81. 81.Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432–45.
82. Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007;31:2392–7. doi:10.1007/s00268-007-9264-3.
83. Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21:e131–41. doi:10.1016/j.suronc.2012.05.001.
84. Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intraarterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18:3657–65. doi:10.1245/s10434-011-1832-y.
85. Elias D, Sideris L, Liberale G, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery. 2005;137:411–6. doi:10.1016/j.surg.2004.11.007.
86. Elias D, David A, Sourrouille I, et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intraabdominal metastases). Surgery. 2014;155:5–12. doi:10.1016/j.surg.2013.05.030.
87. Kianmanesh R, Ruszniewski P, Rindi G, et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010;91:333–40. doi:10.1159/000286700.
88. Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62. doi:10.1159/000111037.
89. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4:29. doi:10.1186/1756-8722-4-29.
90. Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol. 2012;973–946. doi:10.1155/2012/973946.
91. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189–94. doi:10.1056/NEJM198011203032101.
92. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–771. doi:10.1200/JCO.2004.04.024.
93. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23. doi:10.1056/NEJM199202203260804.
94. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75. doi:10.1002/cncr.25425.
95. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5. doi:10.1038/sj.bjc.6690325.
96. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548–54. doi:10.1200/JCO.2005.05.0575.
97. Sorbye H, Wekin S, Langer S, et al. Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3) (abstract). North American Neuroendocrine Society Symposium, Abstract C36 2012.
98. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117:4617–22. doi:10.1002/cncr.26124.
99. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23. doi:10.1056/NEJMoa1009290.
100. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13. doi:10.1056/NEJMoa1003825.
101. 101.Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European Delphi process. Eur J Radiol. 2001;37:8–17.
102. A randomized, double-blind, placebo-controlled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET). The European Cancer Congress; 2013.
103. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30. doi:10.1200/JCO.2007.15.2553.
104. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220–6. doi:10.1159/000225951.
105. Sowa-Staszczak A, Pach D, Stefanska A, et al. Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with nonfunctioning neuroendocrine pancreatic tumours? Nucl Med Rev Cent East Eur. 2011;14:73–8.
106. Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30:1100–6. doi:10.1200/JCO.2011.37.2151.
107. Gulenchyn KY, Yao X, Asa SL, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol R Coll Radiol. 2012;24:294–308. doi:10.1016/j.clon.2011.12.003.
108. 108.Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3:761–71.
109. Fjallskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19:35–42. doi:10.1385/MO:19:1:35.
110. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72. doi:10.1016/S1470-2045(07)70410-2.